These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 22999073)

  • 1. Effect of tailored antiplatelet therapy on periprocedural myonecrosis in patients with diabetes mellitus (from the DM-Verify Now Trial).
    Suh JW; Kim CH; Oh IY; Yoon CH; Kim KI; Cho YS; Youn TJ; Chae IH; Choi DJ
    Am J Cardiol; 2012 Dec; 110(12):1749-55. PubMed ID: 22999073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
    Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial.
    Lee W; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH
    BMC Cardiovasc Disord; 2018 Oct; 18(1):201. PubMed ID: 30348101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
    Mangiacapra F; Patti G; Peace A; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Muller O; Barbato E; Di Sciascio G
    Am J Cardiol; 2010 Sep; 106(5):619-23. PubMed ID: 20723634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
    Ang L; Thani KB; Ilapakurti M; Lee MS; Palakodeti V; Mahmud E
    J Am Coll Cardiol; 2013 Jan; 61(1):23-34. PubMed ID: 23287370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).
    Patti G; Mangiacapra F; Ricottini E; Cannatà A; Cavallari I; Vizzi V; D'Ambrosio A; Dicuonzo G; Di Sciascio G
    Am J Cardiol; 2013 Jun; 111(12):1739-44. PubMed ID: 23538022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
    Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
    Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
    Leonardi S; Thomas L; Neely ML; Tricoci P; Lopes RD; White HD; Armstrong PW; Giugliano RP; Antman EM; Califf RM; Newby LK; Mahaffey KW
    J Am Coll Cardiol; 2012 Dec; 60(22):2296-304. PubMed ID: 23122801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
    J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban.
    Verdoia M; Pergolini P; Barbieri L; Rolla R; Nardin M; Negro F; Suryapranata H; De Luca G;
    Thromb Res; 2018 Apr; 164():17-23. PubMed ID: 29475177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty.
    Okmen E; Sanli A; Uyarel H; Dayi S; Tartan Z; Cam N
    Cardiology; 2004; 102(1):18-23. PubMed ID: 14988614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study.
    Patti G; Colonna G; Pasceri V; Pepe LL; Montinaro A; Di Sciascio G
    Circulation; 2005 Apr; 111(16):2099-106. PubMed ID: 15750189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
    Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
    Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
    Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome.
    Chang SM; Yazbek N; Lakkis NM
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):193-7. PubMed ID: 15170709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.